

Patent Docket P1717

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

van Bruggen et al.

Serial No.: 09/218,481

Filed:

December 22, 1998

For: Vascular Endothelial Cell Growth Factor Antagonists

and Uses Thereof

Group Art Unit: 1642

Examiner: S. Ungar

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

March 7. 2000

E. Faenza

TRANSMITTAL LETTER

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

MAR 15 2000

Transmitted herewith are the following documents: TECH CENTER 1600/2900

- Response to Notice to Comply with Requirements for Patent 1. Application Containing Sequence Disclosures; Response to Restriction Requirement; and Preliminary Amendment.
- 2. Copy of Notice to Comply.
- Petition to Extend Time and \$380.00 Extension Fee. 3.
- Certificate regarding Sequence Listing, Sequence Listing & 4. Diskette.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

> Respectfully submitted, GENENTECH, INC.

MAR 17 2000

Date: March <u>//</u>, 2000

Diane L. Marschang

By: Diane L. Marschang TECH CENTER 1600/2900

Reg. No. 35,600

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-5416 Fax: (650) 952-9881